

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Commissioner
US Department of Commerce
United States Patent and Trademark
Office, PCT
2011 South Clark Place Room
CP2/5C24
Arlington, VA 22202
ETATS-UNIS D'AMERIQUE
in its capacity as elected Office

Date of mailing (day/month/year) 22 May 2001 (22.05.01)	
International application No. PCT/CA00/01043	Applicant's or agent's file reference 80021-217
International filing date (day/month/year) 08 September 2000 (08.09.00)	Priority date (day/month/year) 08 September 1999 (08.09.99)
Applicant KEOWN, Paul et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:
05 April 2001 (05.04.01)

☐ in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was
☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer Charlotte ENGER Telephone No.: (41-22) 338.83.38
---	---

PATENT COOPERATION TREATY

From the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:

KINGWELL, Brian G. et al
SMART & BIGGAR
Box 11560, Vancouver Centre
650 West Georgia Street, Suite 2200
Vancouver, British Columbia V6B 4N8
CANADA

RECEIVED

2001 DEC 20

A 10: 38

PCT

NOTIFICATION OF TRANSMITTAL OF
THE INTERNATIONAL PRELIMINARY
EXAMINATION REPORT
(PCT Rule 71.1)

Date of mailing
(day/month/year)

06.12.2001

Applicant's or agent's file reference
80021-217

IMPORTANT NOTIFICATION

International application No.
PCT/CA00/01043

International filing date (day/month/year)
08/09/2000

Priority date (day/month/year)
08/09/1999

Applicant

THE UNIVERSITY OF BRITISH COLUMBIA et al

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/



European Patent Office
D-80298 Munich
Tel. +49 89 2399 - 0 Tx: 523656 epmu d
Fax: +49 89 2399 - 4465

Authorized officer

Digiusto, M

Tel. +49 89 2399-8162



INTERNATIONAL SEARCH REPORT

International Application No
PCT/CA 00/01043

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, CHEM ABS Data, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	KHANI-HANJANI, A. ET AL.: "Association between dinucleotide repeat in non-coding region of interferon-gamma gene and susceptibility to, and severity of, rheumatoid arthritis" LANCET, vol. 356, 2 September 2000 (2000-09-02), page 820-825 XP002172553 page 823, right-hand column, paragraph 2	1-23
A	RUIZ-LINARES, A.: "Dinucleotide repeat polymorphism in the interferon-gamma (INFG) gene" HUMAN MOLECULAR GENETICS, vol. 2, no. 9, 1993, page 1508 XP002172554 the whole document	1-23
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

19 July 2001

Date of mailing of the international search report

06/08/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Mata Vicente, T.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 00/01043

C.(Continuation) DOCUMENTS CONSIDERED RELEVANT

Category "	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>MOLKENTIN, J. ET AL.: "Molecular analysis of HLA-DRbeta and DQbeta polymorphism in Chinese with rheumatoid arthritis"</p> <p>ANNALS RHEUM. DIS.,</p> <p>vol. 52, 1993, pages 610-612, XP001010295</p> <p>page 610, right-hand column, paragraph 3</p> <p>-----</p>	18-23

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

As far as an "in vivo" method is concerned, claims 1-15 are directed to a diagnostic method practised on the human/animal body and the search has been carried out and based on the alleged effects of the compound/composition.

Although claims 16-23 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 80021-217	FOR FURTHER ACTION <small>see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.</small>	
International application No. PCT/CA 00/01043	International filing date (day/month/year) 08/09/2000	(Earliest) Priority Date (day/month/year) 08/09/1999
Applicant THE UNIVERSITY OF BRITISH COLUMBIA		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 5 sheets.
☒ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.
- ☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).
- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :
- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☒ furnished subsequently to this Authority in written form.
- ☒ furnished subsequently to this Authority in computer readable form.
- ☒ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☒ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☒ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

- ☒ the text is approved as submitted by the applicant.
- ☐ the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

- ☒ the text is approved as submitted by the applicant.
- ☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

- ☒ as suggested by the applicant.
- ☐ because the applicant failed to suggest a figure.
- ☐ because this figure better characterizes the invention.
- 1 ☐ None of the figures.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

As far as an "in vivo" method is concerned, claims 1-15 are directed to a diagnostic method practised on the human/animal body and the search has been carried out and based on the alleged effects of the compound/composition.

Although claims 16-23 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

INTERNATIONAL SEARCH REPORT

International Application No

/CA 00/01043

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, CHEM ABS Data, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	KHANI-HANJANI, A. ET AL.: "Association between dinucleotide repeat in non-coding region of interferon-gamma gene and susceptibility to, and severity of, rheumatoid arthritis" LANCET, vol. 356, 2 September 2000 (2000-09-02), page 820-825 XP002172553 page 823, right-hand column, paragraph 2 ---	1-23
A	RUIZ-LINARES, A.: "Dinucleotide repeat polymorphism in the interferon-gamma (INFG) gene" HUMAN MOLECULAR GENETICS, vol. 2, no. 9, 1993, page 1508 XP002172554 the whole document --- -/--	1-23

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

19 July 2001

Date of mailing of the international search report

06/08/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Mata Vicente, T.

INTERNATIONAL SEARCH REPORT

International Application No

/CA 00/01043

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>MOLKENTIN, J. ET AL.: "Molecular analysis of HLA-DRbeta and DQbeta polymorphism in Chinese with rheumatoid arthritis" ANNALS RHEUM. DIS., vol. 52, 1993, pages 610-612, XP001010295 page 610, right-hand column, paragraph 3 -----</p>	18-23

PATENT COOPERATION TREATY

From the:
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:

KINGWELL, Brian G. et al
SMART & BIGGAR
Box 11560, Vancouver Centre
650 West Georgia Street, Suite 2200
Vancouver, British Columbia V6B 4H6
CANADA

PCT

CONFIRMATION

WRITTEN OPINION

(PCT Rule 66)

Date of mailing
(day/month/year)

27.08.2001

Applicant's or agent's file reference

80021-217

REPLY DUE

within 2 month(s)
from the above date of mailing

International application No.

PCT/CA00/01043

International filing date (day/month/year)

08/09/2000

Priority date (day/month/year)

08/09/1999

International Patent Classification (IPC) or both national classification and IPC

C12Q1/68

Applicant

THE UNIVERSITY OF BRITISH COLUMBIA et al

1. This written opinion is the **first** drawn up by this International Preliminary Examining Authority.

2. This opinion contains indications relating to the following items:

- I ☒ Basis of the opinion
- II ☐ Priority
- III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain document cited
- VII ☐ Certain defects in the international application
- VIII ☒ Certain observations on the international application

3. The applicant is hereby **invited to reply** to this opinion.

When? See the time limit indicated above. The applicant may, before the expiration of that time limit, request this Authority to grant an extension, see Rule 66.2(d).

How? By submitting a written reply, accompanied, where appropriate, by amendments, according to Rule 66.3. For the form and the language of the amendments, see Rules 66.8 and 66.9.

Also: For an additional opportunity to submit amendments, see Rule 66.4.
For the examiner's obligation to consider amendments and/or arguments, see Rule 66.4 bis.
For an informal communication with the examiner, see Rule 66.6.

If no reply is filed, the international preliminary examination report will be established on the basis of this opinion.

4. The final date by which the international preliminary examination report must be established according to Rule 69.2 is: **08/01/2002**.

Name and mailing address of the international preliminary examining authority:



European Patent Office
D-80298 Munich
Tel. +49 89 2399 - 0 Tx: 523656 epmu d
Fax: +49 89 2399 - 4465

Authorized officer / Examiner

Wagner, R

Formalities officer (incl. extension of time limits)

Digiusto, M

Telephone No. +49 89 2399 8162



WRITTEN OPINION

International application No. PCT/CA00/01043

1. Basis of the opinion

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this opinion as "originally filed"*):

Description, pages:

1-16 as originally filed

Claims, No.:

1-23 as originally filed

Drawings, sheets:

1/3-3/3 as originally filed

Sequence listing part of the description, pages:

1-33, filed with the letter of 17.10.2000

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☒ furnished subsequently to this Authority in written form.
- ☒ furnished subsequently to this Authority in computer readable form.
- ☒ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☒ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

WRITTEN OPINION

International application No. PCT/CA00/01043

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been and will not be examined in respect of:

- ☐ the entire international application,
- ☒ claims Nos. 1-23,

because:

- ☒ the said international application, or the said claims Nos. 1-15 regarding industrial applicability relate to the following subject matter which does not require an international preliminary examination (*specify*):
see separate sheet
- ☒ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. 16-23 are so unclear that no meaningful opinion could be formed (*specify*):
see separate sheet
- ☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.
- ☐ no international search report has been established for the said claims Nos. .

2. A written opinion cannot be drawn due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

- ☐ the written form has not been furnished or does not comply with the standard.
- ☐ the computer readable form has not been furnished or does not comply with the standard.

V. Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement
Novelty (N)

Claims

WRITTEN OPINION

International application No. PCT/CA00/01043

Inventive step (IS) Claims

Industrial applicability (IA) Claims

2. Citations and explanations
see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:
see separate sheet

Re Item III

Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. Claims 1-15 (as far as in vivo methods are concerned) relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(i) PCT).
2. Claims 16 and dependent claims 17-23 are directed to a method of treatment but the features of said claims are limiting a method of diagnosis. Therefore claims 16-23 are not clear (Article 6 PCT) because they do not contain any features limiting the claimed method.

Re Item V

Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

Reference is made to the following documents:

D1: KHANI-HANJANI, A. ET AL.: 'Association between dinucleotide repeat in non-coding region of interferon-gamma gene and susceptibility to, and severity of, rheumatoid arthritis' LANCET, vol. 356, 2 September 2000 (2000-09-02), page 820-825 XP002172553

1. Document D1 is published after the priority date claimed by the present application and before the date of international filing. It appears that D1 is a publication of the present invention. As the validity of the claimed priority cannot be examined in the present written opinion, the priority is considered to be valid and D1 is considered not to form part of the prior art.
2. The subject-matter of claims 1-15 is new (Article 33(2) PCT) because the available prior art does not disclose that rheumatoid arthritis can be diagnosed by

identifying a certain allele of the interferon gamma gene. The prior art does not give any indication that a linkage exists between the presence of certain alleles of the interferon gamma gene and the occurrence of rheumatoid arthritis. Therefore the subject-matter of claims 1-15 involves an inventive step (Article 33(3) PCT).

Re Item VIII

Certain observations on the international application

1. Claims 1-5 and 7 to 15 are not supported by the description (Article 6 PCT) and not sufficiently disclosed (Article 5 PCT) over the entire width of their scope because said claims refer to arthritis in general. Arthritis is an inflammation of a joint which can for example be due to an infection. The present application only provides substantive support for a diagnosis of rheumatoid arthritis.
2. Claims 2 and 11 are not clear (Article 6 PCT) because the formulation "a first intron" could imply that the gene has several first introns (e.g. depending if the gene is observed in a 3'-5' or 5'-3' direction).
3. Claims 4 and 14 are not clear (Article 6 PCT) because the alleles are identified by an internal denomination. The alleles should be identified by the respective Seq. Id. Nos.

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 80021-217	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/CA00/01043	International filing date (day/month/year) 08/09/2000	Priority date (day/month/year) 08/09/1999
International Patent Classification (IPC) or national classification and IPC C12Q1/68		
Applicant THE UNIVERSITY OF BRITISH COLUMBIA et al		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.


2. This REPORT consists of a total of 6 sheets, including this cover sheet.

☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand 05/04/2001	Date of completion of this report 06.12.2001
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer Wagner, R Telephone No. +49 89 2399 7357



**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/CA00/01043

I. Basis of the report

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

Description, pages:

1-16 as originally filed

Claims, No.:

1-23 as originally filed

Drawings, sheets:

1/3-3/3 as originally filed

Sequence listing part of the description, pages:

1-33, filed with the letter of 17.10.2000

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☒ furnished subsequently to this Authority in written form.
- ☒ furnished subsequently to this Authority in computer readable form.
- ☒ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☒ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/CA00/01043

- ☐ the description, pages:
☐ the claims, Nos.:
☐ the drawings, sheets:
5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):
(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

☐ the entire international application.

☒ claims Nos. 1-23.

because:

☒ the said international application, or the said claims Nos. 1-15 regarding industrial applicability relate to the following subject matter which does not require an international preliminary examination (*specify*):
see separate sheet

☒ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. 16-23 are so unclear that no meaningful opinion could be formed (*specify*):
see separate sheet

☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.

☐ no international search report has been established for the said claims Nos. .

2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

☐ the written form has not been furnished or does not comply with the standard.

☐ the computer readable form has not been furnished or does not comply with the standard.

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/CA00/01043

1. Statement

Novelty (N)	Yes:	Claims 1-15
	No:	Claims
Inventive step (IS)	Yes:	Claims 1-15
	No:	Claims
Industrial applicability (IA)	Yes:	Claims
	No:	Claims

2. Citations and explanations
see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:
see separate sheet

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/CA00/01043

Re Item III

Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. Claims 1-15 (as far as in vivo methods are concerned) relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(i) PCT).
2. Claims 16 and dependent claims 17-23 are directed to a method of treatment but the features of said claims are limiting a method of diagnosis. Therefore claims 16-23 are not clear (Article 6 PCT) because they do not contain any features limiting the claimed method.

Re Item V

Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement.

Reference is made to the following documents:

D1: KHANI-HANJANI, A. ET AL.: 'Association between dinucleotide repeat in non-coding region of interferon-gamma gene and susceptibility to, and severity of, rheumatoid arthritis' LANCET, vol. 356, 2 September 2000 (2000-09-02), page 820-825 XP002172553

1. Document D1 is published after the priority date claimed by the present application and before the date of international filing. It appears that D1 is a publication of the present invention. As the claimed priority appears to be valid, D1 is considered not to form part of the prior art.
2. The subject-matter of claims 1-15 is new (Article 33(2) PCT) because the available prior art does not disclose that rheumatoid arthritis can be diagnosed by identifying a certain allele of the interferon gamma gene. The prior art does not give any indication that a linkage exists between the presence of certain alleles of

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/CA00/01043

the interferon gamma gene and the occurrence of rheumatoid arthritis. Therefore the subject-matter of claims 1-15 involves an inventive step (Article 33(3) PCT).

Re Item VIII

Certain observations on the international application

1. Claims 1-5 and 7 to 15 are not supported by the description (Article 6 PCT) and not sufficiently disclosed (Article 5 PCT) over the entire width of their scope because said claims refer to arthritis in general. Arthritis is an inflammation of a joint which can for example be due to an infection. The present application only provides substantive support for a diagnosis of rheumatoid arthritis..
2. Claims 2 and 12 are not clear (Article 6 PCT) because the formulation "a first intron" could imply that the gene has several first introns (e.g. depending if the gene is observed in a 3'-5' or 5'-3' direction).
3. Claims 4 and 14 are not clear (Article 6 PCT) because the alleles are identified by an internal denomination. The alleles should be identified by the respective Seq. Id. Nos.

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
15 March 2001 (15.03.2001)

PCT

(10) International Publication Number
WO 01/18240 A2(51) International Patent Classification⁷: C12Q 1/68

(21) International Application Number: PCT/CA00/01043

(22) International Filing Date:
8 September 2000 (08.09.2000)

(25) Filing Language: English

(26) Publication Language: English


(30) Priority Data:
2,282,062 8 September 1999 (08.09.1999) CA
60/160,618 20 October 1999 (20.10.1999) US
2,303,504 10 April 2000 (10.04.2000) CA(71) Applicant (for all designated States except US): THE
UNIVERSITY OF BRITISH COLUMBIA [CA/CA];University-Industry Liaison Office, IRC Building, Room
331, 2194 Health Sciences Mall, Vancouver, British
Columbia V6T 1Z3 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): KEOWN, Paul
[CA/CA]; Immunology Laboratory, Vancouver General
Hospital, 855 West 12th Avenue, Vancouver, British
Columbia V5Z 1M9 (CA). KHANI-HANJANI, Abbas
[CA/CA]; Immunology Laboratory, Vancouver General
Hospital, 855 West 12th Avenue, Vancouver, British
Columbia V5Z 1M9 (CA). HOAR, David [CA/CA];
Immunology Laboratory, Vancouver General Hospital,
855 West 12th Avenue, Vancouver, British Columbia V5Z
1M9 (CA).(74) Agents: KINGWELL, Brian, G. et al.; Smart & Biggar,
Box 11560, Vancouver Centre, 650 West Georgia Street,
Suite 2200, Vancouver, British Columbia V6B 4N8 (CA).

[Continued on next page]

(54) Title: DIAGNOSTIC AND THERAPEUTIC METHODS IN AUTOIMMUNE DISEASE



(57) Abstract: In one aspect, the invention provides a method of diagnosis. The diagnostic method may include steps of identifying a patient at risk of an arthritis, the patient having an interferon gamma gene. The patient may be tested to characterize a polymorphism in a first intron of the interferon gamma gene. The polymorphism may comprise a variable length dinucleotide repeat region within the first intron, and the dinucleotide repeat region may be located at least partly between nucleotides 1349 and 1373 in the interferon, gamma gene. The method may be carried out so as to be capable of identifying alleles such as the 126 bp allele and the 122 bp allele, as further described herein. The polymorphisms may be distinguished based on a difference in the number of CA repeats in a portion of the first intron of the interferon gamma gene. The invention may also comprise testing a patient for a polymorphism in an HLA protein (or gene), such as the HLA-DRB1 protein.



(81) **Designated States (national):** AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) **Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European

patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

DIAGNOSTIC AND THERAPEUTIC METHODS IN AUTOIMMUNE DISEASE

FIELD OF THE INVENTION

5 The invention is in the field of pharamacogenomics, particularly the utilization of genetic alleles as diagnostic markers.

BACKGROUND OF THE INVENTION

10 Rheumatoid arthritis is a chronic polyarticular inflammatory disease with a variable course and outcome (Combe et al., 1995, *Br. J. Rheumatol.* 34: 529). Clinical expression ranges from a mild, non-deforming arthropathy with little long-term disability to severe, incapacitating, erosive articular destruction which may be refractory to conventional disease modifying agents (Schiff, 1997, *Am. J. Med.* 102 (suppl 1A): 11S-15S). Prediction of disease progression is imprecise, and is often based on a combination of demographic, clinical and
15 laboratory factors, including low socioeconomic status and educational levels, severe initial disease activity, systemic manifestations and extra-articular features, the early appearance of joint erosions, an elevated erythrocyte sedimentation rate, C-reactive protein and the presence of rheumatoid factor. There is epidemiological evidence that there is a genetic relationship between loci in the major histocompatibility complex (MHC) class II region and disease
20 susceptibility and severity (Reveille, 1998, *Curr. Op. Rheumatol.* 10: 187; Nepom et al., 1996, *J.Rheumatol.* 23 (suppl 44): 5; Weyand and Goronzy, 1995, *Curr. Op. Rheumatol.* 7: 206).

25 Interferon gamma is a homodimeric 34 Kd peptide. IFN gamma may be secreted by T-lymphocytes under certain conditions of activation and by NK cells (Boehm, U., et al. 1997). IFN gamma binds to cell surface receptors on cellular targets including mononuclear phagocytes, endothelial cells and NK cells, and is thought to play an important role in the coordinated regulation and expression of the immune response through the stimulation or repression of genes (Farrar, M.A. et al., 1993; Revel, M. et al., 1986). IFN gamma appears to
30 be produced by T-cells infiltrating the inflamed synovium and may be secreted into the joint space, but the role of this peptide in the progression of the articular injury in arthritis remains controversial (Feldemann, M. et al. 1996).

IFN gamma is encoded by a gene which in humans is mapped to 12q24 on chromosome 12. The known sequence of the gene consists of 4 exons with 3 intervening regions. A variable length dinucleotide repeat polymorphism has been described in humans and lower primates within the first intron of this gene, between positions 1349 and 1373. The number of alleles reported at this microsatellite region appears to vary according to the detection methodology employed to characterize it (Ruiz-Linares A, 1993; Awata, T. et al. 1994; Pravica, V. et al., 1998).

The human leukocyte antigens (HLA) are a family of polymorphic cell-surface proteins that are involved in intercellular interactions in the immune system. The HLA genes are part of the major histocompatibility complex (MHC). The HLA proteins are designated HLA-A, -B, -DR, -DQ and -DP. The HLA-A, -B and -C proteins are described as Class I HLA proteins, while the HLA-DR, -DQ and -DP proteins are described as Class II proteins, and are composed of two polypeptide chains, an alpha chain and a highly polymorphic beta chain.

The Class II HLA proteins are expressed on the cell surface of macrophages, B-cells and activated T-cells, where they are thought to be involved in binding and presenting antigens to helper T-lymphocytes (see Giles and Capra, 1985, Adv. Immunol. 37:1). The Class II DP, DQ and DR genes are located in separate regions of the MHC (Trowsdale *et al.*, 1985, Immunol. Rev. 85:5). In the DR region, the DRA locus encodes the alpha chain and five different DRB loci encode the beta chain: DRB1, DRB2 (now known as DRB6), DRB3, DRB4, and DRB5.

The Class II protein genes have been segregated into a number of known haplotypes (the specific allele combination at multiple loci on the same chromosome, see for example Dupont, 1989, Hum. Immunol. 26:3), such as the DR4 haplotype which may be associated with rheumatoid arthritis. Some efforts have been made to determine which locus within the DR4 haplotype is most tightly associated with predisposition to rheumatoid arthritis (Zanelli *et al.*, 1998, Immunogenetics 48:394-401). A complex interrelationship of loci appears to be involved in various aspect of rheumatoid arthritis, including a 'shared epitope' Q(K/R)RAA at amino acids 70-74 of the *DRB1* encoded peptide. This shared epitope has been associated

with severe rheumatoid arthritis (Gregerson *et al.*, 1987, Arthritis Rheum 30:1205-1213; Williams *et al.*, 1993, DNA and Cell Biology 12(5):425-434), although its frequency in the normal population has been suggested to preclude its use as a positive indicator of disease prognosis (Khani-Hanjani *et al.*, 1998, Abstract 293, Poster Session B, American College of Rheumatology 62nd National Meeting). The role of specific residues within the shared epitope of *DRB1* has been investigated (Zanelli *et al.*, 1997, J. Immunol 158:3545-3551; Wucherpennig *et al.*, 1995, Proc. Natl. Acad. Sci. 92:11935-11939).

SUMMARY OF THE INVENTION

In one aspect, the invention provides a method of diagnosis. The diagnostic method may include steps of identifying a patient at risk of an arthritis, the patient having an interferon gamma gene. The patient may be tested to characterize a polymorphism in a first intron of the interferon gamma gene. The polymorphism may comprise a variable length dinucleotide repeat region within the first intron, and the dinucleotide repeat region may be located at least partly between nucleotides 1349 and 1373 in the interferon gamma gene. The method may be carried out so as to be capable of identifying alleles such as the 126 bp allele and the 122 bp allele, as further described herein. The polymorphisms may be distinguished based on a difference in the number of CA repeats in a portion of the first intron of the interferon gamma gene. To characterize the polymorphism, a region of the first intron may be amplified, such as a region comprising a variable length dinucleotide repeat.

The use of an allele of an interferon, gamma gene as described herein may provide prognostic information with respect to the likelihood of particular clinical outcomes for the patient, and as a result may be utilized to modify treatment regimens. In particular, the presence of alleles associated with relatively severe disease, such as the 126 bp allele, may be taken as an indication that aggressive therapy should be pursued relatively early in the progression of the disease.

In one aspect, the invention involves the identification of high and low risk interferon gamma alleles. In another aspect, the invention involves a further refinement of patient differentiation involving the use of an HLA locus in conjunction with the IFN locus.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a risk analysis tree showing the association between the severity of RA (severe or mild disease) and the IFN gamma (shown by the arrow labelled "IFN") and *HLA-DRB1* (shown by the arrow labelled "HLA") genotype of the patient.

ii.

Figure 2 shows the *HLA-DRB1* amino acid sequences 70-74 for both alleles for patients with severe RA.

Figure 3 shows the *HLA-DRB1* amino acid sequences 70-74 for both alleles for patients with mild RA.

DETAILED DESCRIPTION OF THE INVENTION

In one aspect, the invention discloses a correlation between two alleles, designated 126 bp and 122 bp, and the occurrence of particular disease states in arthritis. There is a positive correlation between the occurrence of the 126 bp allele and severe rheumatoid arthritis. There is a negative correlation between the occurrence of the 122 bp allele and severe rheumatoid arthritis. For each allele, there is a corresponding and reverse correlation with relatively mild rheumatoid arthritis. One aspect of the present invention therefore provides pharmacogenomic methods to assist in diagnosis of arthritis disease, including prediction of disease severity and selection of therapy regimens in particular patients.

In another aspect, the invention discloses embodiments of partial DNA sequences corresponding to the 122 bp, 124 bp and 126 bp alleles. Alleles which share a particular PCR fragment length, such as the 122 bp alleles, need not be identical in all other respects. In effect, there may be a 'family' of alleles characterized by a particular PCR amplification fragment size. Sequencing of individual embodiments of the alleles of interest produced the following sequence information (in which "N" indicates that it was not possible to unambiguously identify the base at the relevant position):

A 122 bp fragment partial sequence:

AACCACAAATNCAATNCTCACACACACACACACACACACCC
NNANATTTTGGAAACNANCTTTAAANCCNCNNAAAAAAAAAANNCCCN
ANAGNANGGT

A 124 bp fragment partial sequence:

AAAACCACAAAATTCAAATNCNCACACACACACACACACACAC
ACNCCCANATTTTTTGNNANANNCTTTTAAACCCCTNAAAAAAAAAN
CCCCANANGNGAGNGGGGAT

A 126 bp fragment partial sequence:

AAANCCACAAAATTCAAATNCACACACACACACACACACACACA
CACCCACANATTTTTTGGAACNANCTTTAAANCCCCNAAAAAAAAA
ACCCCAANAGGGGANGGGGATN

The various alleles have been found to have different numbers of CA repeats according to their fragment size, as follows:

120 bp allele: 11 CA repeats

122 bp allele: 12 CA repeats

124 bp allele: 13 CA repeats

126 bp allele: 14 CA repeats

128 bp allele: 15 CA repeats

130 bp allele: 16 CA repeats

Hutchinson et al., 1999, *Transplant Proc.*, 31(1-2): 734, indicate that the allele containing the 122 bp fragment, is associated with high levels of IFN-gamma production, while other alleles, including the 126 bp allele, are associated with low levels of IFN-gamma production. Accordingly, in one aspect, the invention provides for a genotyping assay to identify IFN-gamma alleles that are associated with low levels of IFN-gamma production, to provide an indication that the patient having the allele is likely to suffer from severe rheumatoid arthritis. Conversely, the invention provides assays for identifying IFN-gamma alleles associated with high levels of IFN-gamma production to provide an indication that the patient having such an allele is less likely to suffer from severe rheumatoid arthritis.

The invention may be utilized in patients identified as at risk of an arthritis, such as patients diagnosed by a medical practitioner as suffering from RA. Patients may for example be identified as at risk of an arthritis on the basis epidemiological criteria such as sex, age, socioeconomic factors or family history, on the basis of which an assessment may be made that the patient is more likely than other persons to suffer from an arthritis. Physicians typically diagnose RA based on the overall pattern of symptoms, medical history, physical

exam, X-rays and tests for rheumatoid factor or established genetic markers such as HLA-DR4. Typical symptoms of patients at risk of RA may include: general fatigue, soreness, stiffness and aching, with pain and swelling typically occurring in the same joints on both sides of the body and starting in the hands or feet, particularly the wrist and many of the hand joints. Other diagnostic symptoms may include rheumatoid nodules. The diagnosis of the patient as being at risk of an arthritis may also comprise identifying symptoms such as the following: joint erosions, elevated erythrocyte sedimentation rate, C-reactive protein, polyarticular disease, joint deformities, radiological evidence of subchondral erosions, extra-articular arthritis or the presence of rheumatoid factor. Patients may be identified as at risk by virtue of an inadequate response to one or more arthritis therapies, such as an inadequate response to DMARDs (disease-modifying antirheumatic drugs) or other medicaments for treating the arthritis.

In one aspect, the invention provides a method of treating a patient having an interferon gamma gene, comprising testing the patient to characterize a polymorphism in the interferon gamma gene; and, treating the patient for an arthritis if the polymorphism indicates that the patient is at risk of an arthritis. The polymorphism in the interferon gamma gene may be in the length of the dinucleotide repeat region within the first intron. The presence of the high risk allele of the present invention may for example be taken as indicative of susceptibility to arthritis or to a more severe form of arthritis.

In accordance with various aspects of the invention, a patient may be treated for an arthritis. For example, treating a patient for RA may comprise administering to the patient an effective amount of a medicament. An effective amount of a medicament may be a therapeutically effective amount or a prophylactically effective amount. A "therapeutically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result, such as reducing signs and symptoms of RA and delaying structural damage of RA. A therapeutically effective amount of a therapeutic may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the therapeutic to elicit a desired response in the individual. Dosage regimens may be adjusted to provide the optimum therapeutic response. A therapeutically effective amount is also typically one in which any toxic or detrimental effects of the therapeutic are

outweighed by the therapeutically beneficial effects. A "prophylactically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result, such as reducing signs and symptoms of RA and delaying structural damage of RA. A prophylactic dose may be used in subjects prior to or at an earlier stage of disease, and a prophylactically effective amount may be more or less than a therapeutically effective amount in some cases.

Medicaments for treating an arthritis may for example include drugs approved by the FDA for treating patients with moderately to severely active rheumatoid arthritis, such as drugs that reduce signs and symptoms of RA and delay structural damage of RA in patients. Such drugs may for example include: nonsteroidal anti-inflammatory drugs (NSAIDs), COX-2 inhibitors such as celecoxib (*Celebrex*) or rofecoxib (*Vioxx*), salicylates, glucocorticoids, TNF inhibitors such as infliximab (*Remicade*), DMARDs such as leflunomide (*Arava*), cyclosporine, mycophenolate mofetil (*Cellcept*), anti-TNF antibodies (as described in US Patent No. 5,698,195), methotrexate, or soluble versions of the TNF receptor (such as ENBREL(TM), available from Immunex Corp. of Seattle, Washington, USA) or the IL-1 receptor.

In one aspect, the invention relates to the use in gene therapy of an IFN gamma nucleic acid. The IFN gamma nucleic acid may be delivered by a therapeutically acceptable gene therapy vector to modify a patient's IFN gamma allele profile. Gene therapy may for example be used to replace a high risk IFN gamma allele with a low risk IFN gamma allele.

Gene therapy vectors may for example be an adeno-associated vector (AAV). Such a vector may comprise for example: a 5' inverted terminal repeat (ITR); a promoter, such as a CMV enhancer-promoter with a muscle specific enhancer; an intron; a 3'-untranslated region (3'-UTR); a polyadenylation signal, such as an SV40 polyadenylation signal; and a 3'-ITR. For gene therapy vectors, the dosage to be administered may depend to a large extent on the condition and size of the subject being treated as well as the therapeutic formulation, frequency of treatment and the route of administration. Regimens for continuing therapy, including dose, formulation, and frequency may be guided by the initial response and clinical judgment. The parenteral route of injection into the interstitial space of tissue may be preferred, although other parenteral routes, such as inhalation of an aerosol formulation, may

be required in specific administration. In some protocols, a formulation comprising the gene and gene delivery system in an aqueous carrier is injected into tissue in appropriate amounts. The tissue target may be specific, for example the muscle or liver tissue, or it may be a combination of several tissues, for example the muscle and liver tissues. Exemplary tissue targets may include liver, skeletal muscle, heart muscle, adipose deposits, kidney, lung, vascular endothelium, epithelial and/or hematopoietic cells. A nucleic acid of the invention may be delivered to cells *in vivo* using methods such as direct injection of DNA, receptor-mediated DNA uptake, viral-mediated transfection or non-viral transfection and lipid based transfection, all of which may involve the use of gene therapy vectors. Direct injection has been used to introduce naked DNA into cells *in vivo* (see e.g., Acsadi et al. (1991) Nature 332:815-818; Wolff et al. (1990) Science 247:1465-1468). A delivery apparatus (e.g., a "gene gun") for injecting DNA into cells *in vivo* may be used. Such an apparatus may be commercially available (e.g., from BioRad). Naked DNA may also be introduced into cells by complexing the DNA to a cation, such as polylysine, which is coupled to a ligand for a cell-surface receptor (see for example Wu, G. and Wu, C. H. (1988) J. Biol. Chem. 263:14621; Wilson et al. (1992) J. Biol. Chem. 267:963-967; and U.S. Pat. No. 5,166,320). Binding of the DNA-ligand complex to the receptor may facilitate uptake of the DNA by receptor-mediated endocytosis. A DNA-ligand complex linked to adenovirus capsids which disrupt endosomes, thereby releasing material into the cytoplasm, may be used to avoid degradation of the complex by intracellular lysosomes (see for example Curiel et al. (1991) Proc. Natl. Acad. Sci. USA 88:8850; Cristiano et al. (1993) Proc. Natl. Acad. Sci. USA 90:2122-2126). Defective retroviruses are well characterized for use as gene therapy vectors (for a review see Miller, A. D. (1990) Blood 76:271). Protocols for producing recombinant retroviruses and for infecting cells *in vitro* or *in vivo* with such viruses can be found in Current Protocols in Molecular Biology, Ausubel, F. M. et al. (eds.) Greene Publishing Associates, (1989), Sections 9.10-9.14 and other standard laboratory manuals. Examples of suitable retroviruses include pLJ, pZIP, pWE and pEM which are well known to those skilled in the art. Examples of suitable packaging virus lines include .pψi.Crip, .pψi.Cre, .pψi.2 and .pψi.Am. Retroviruses have been used to introduce a variety of genes into many different cell types, including epithelial cells, endothelial cells, lymphocytes, myoblasts, hepatocytes, bone marrow cells, *in vitro* and/or *in vivo* (see for example Eglitis, et al. (1985) Science 230:1395-1398; Danos and Mulligan (1988) Proc. Natl. Acad. Sci. USA 85:6460-6464; Wilson et al.

(1988) Proc. Natl. Acad. Sci. USA 85:3014-3018; Armentano et al. (1990) Proc. Natl. Acad. Sci. USA 87:6141-6145; Huber et al. (1991) Proc. Natl. Acad. Sci. USA 88:8039-8043; Ferry et al. (1991) Proc. Natl. Acad. Sci. USA 88:8377-8381; Chowdhury et al. (1991) Science 254:1802-1805; van Beusechem et al. (1992) Proc. Natl. Acad. Sci. USA 89:7640-7644; Kay et al. (1992) Human Gene Therapy 3:641-647; Dai et al. (1992) Proc. Natl. Acad. Sci. USA 89:10892-10895; Hwu et al. (1993) J. Immunol. 150:4104-4115; U.S. Pat. No. 4,868,116; U.S. Pat. No. 4,980,286; PCT Application WO 89/07136; PCT Application WO 89/02468; PCT Application WO 89/05345; and PCT Application WO 92/07573).

10 For use as a gene therapy vector, the genome of an adenovirus may be manipulated so that it includes an IFN gamma nucleic acid, but is inactivated in terms of its ability to replicate in a normal lytic viral life cycle. See for example Berkner et al. (1988) BioTechniques 6:616; Rosenfeld et al. (1991) Science 252:431-434; and Rosenfeld et al. (1992) Cell 68:143-155. Suitable adenoviral vectors derived from the adenovirus strain Ad
15 type 5 dl324 or other strains of adenovirus (e.g., Ad2, Ad3, Ad7 etc.) are well known to those skilled in the art. Recombinant adenoviruses are advantageous in that they do not require dividing cells to be effective gene delivery vehicles and can be used to infect a wide variety of cell types, including airway epithelium (Rosenfeld et al. (1992) cited supra), endothelial cells (Lemarchand et al. (1992) Proc. Natl. Acad. Sci. USA 89:6482-6486), hepatocytes
20 (Herz and Gerard (1993) Proc. Natl. Acad. Sci. USA 90:2812-2816) and muscle cells (Quantin et al. (1992) Proc. Natl. Acad. Sci. USA 89:2581-2584).

Adeno-associated virus (AAV) may be used as a gene therapy vector for delivery of DNA for gene therapy purposes. AAV is a naturally occurring defective virus that requires
25 another virus, such as an adenovirus or a herpes virus, as a helper virus for efficient replication and a productive life cycle (Muzyczka et al. Curr. Topics in Micro. and Immunol. (1992) 158:97-129). AAV may be used to integrate DNA into non-dividing cells (see for example Flotte et al. (1992) Am. J. Respir. Cell. Mol. Biol. 7:349-356; Samulski et al. (1989) J. Virol. 63:3822-3828; and McLaughlin et al. (1989) J. Virol. 62:1963-1973). An AAV
30 vector such as that described in Tratschin et al. (1985) Mol. Cell. Biol. 5:3251-3260 may be used to introduce DNA into cells (see for example Hermonat et al. (1984) Proc. Natl. Acad. Sci. USA 81:6466-6470; Tratschin et al. (1985) Mol. Cell. Biol. 4:2072-2081; Wondisford et

al. (1988) Mol. Endocrinol. 2:32-39; Tratschin et al. (1984) J. Virol. 51:611-619; and Flotte et al. (1993) J. Biol. Chem. 268:3781-3790). Lentiviral gene therapy vectors may also be adapted for use in the invention.

5 General methods for gene therapy are known in the art. See for example, U.S. Pat. No. 5,399,346 by Anderson *et al.* (incorporated herein by reference). A biocompatible capsule for delivering genetic material is described in PCT Publication WO 95/05452 by Baetge *et al.* Methods of gene transfer into hematopoietic cells have also previously been reported (see Clapp, D. W., et al., Blood 78: 1132-1139 (1991); Anderson, Science 288:627-9
10 (2000); and , Cavazzana-Calvo *et al.*, Science 288:669-72 (2000), all of which are incorporated herein by reference).

EXAMPLE 1

48 adult Caucasian patients with severe rheumatoid arthritis and 39 patients with mild
15 rheumatoid arthritis were selected sequentially from a hospital patient population. 50 patients that did not present with symptoms of arthritic disease were selected as a control comparator group. Patients with severe rheumatoid arthritis were aged 58 ± 12 years and were predominantly female and had a mean disease duration of 19 ± 12 years. All such patients had clinically severe polyarticular disease with joint deformities and radiological evidence of
20 subchondral erosions. 75% of such patients had extra-articular manifestations of disease other than the sicca syndrome. 87% of patients with severe rheumatoid arthritis were rheumatoid factor positive. All such patients had not responded favourably to therapy with conventional disease-modifying anti-rheumatic drugs (DMRDS), and had been maintained on cyclosporine treatment for a mean period of 26 months.

25

Patients with mild disease were aged 61 ± 13 years, predominantly female, and had a mean disease duration of 12 ± 7 years. All such patients had clinically mild disease, which had been controlled for a mean period of 90 months by antimalarials alone without prior or current use of DMRDS. Only 26% of such patients had joint deformities, and 36% had extra-
30 articular disease manifestations other than sicca syndrome. 34% of such patients were rheumatoid factor positive.

Peripheral blood was obtained from patients and control subjects, and genomic DNA extracted by proteinase K digestion and by salting out. Molecular typing at the IFN gamma (12q24.12) microsatellite polymorphism was performed by PCR followed by use of a DNA sequencer and gene analysis software. Locus or group-specific amplification was performed using 5' and 3' oligonucleotide amplification primers as follows:

5'6 FAMAG ACA TTC ACA ATT GAT TTT ATT CTT AC 3'

5' CCT TCC TGT AGG GTA TTA TTA TAC G3'

The primers were designed with a high annealing temperature to enhance specificity. The primers were obtained from Perkin-Elmer-ABI-PRISM and the forward primer was fluorescently labelled at the 5' end.

Genomic DNA (100 ng) was amplified using 50 pmoles each of the oligonucleotide primers, 100 uM, each of dNTP, 1.5 mM MgCl₂ and 0.8u of TAQ polymerase in a Perkin-Elmer PCR cycler. Cycling conditions included a 5-minute hot start at 95° C. followed by 32 cycles of 95° C for 45 seconds (denaturation) and 62° C for one minute (annealing and extension) with a final extension of 5 minutes at 62° C in the last cycle. The amplified product was run on a 1.5% agarose gel for detection of positive amplification and then on a long-range gel on a 377 DNA sequencer ABI-PRISM) data were collected using 377 collection software and size analysis was performed using Genescan 2.0.2 software and Genescan 2.0.2 software and Genescan-500 ROX as a size standard (ABI-PRISM).

A total of six alleles were documented in the patients and controls, ranging in length from 120 bp to 130 bp, as shown in Table 1.

TABLE 1: Proportion of subjects expressing individual alleles in the first intron of the IFN γ gene. Controls (n=50), patients with severe RA (n=48), patients with mild RA (n=39).

IFN γ Alleles (Size)	Controls	Severe RA			Mild RA			OR ^b	p ^b
	%	%	OR ^a	P ^a	%	OR ^a	p ^b		
A2 (130 bp)	0	6	7.77	NS	0	-	-	6.08	NS
A3 (128 bp)	16	15	0.90	NS	15	0.95	NS	0.94	NS
A4 (126 bp)	12	73	19.74	p<0.0001	21	1.89	NS	10.43	p<0.0001
A5 (124 bp)	68	77	1.58	NS	67	0.94	NS	1.68	NS
A6 (122 bp)	68	6	0.019	p<0.0001	64	0.50	NS	0.037	p<0.0001
A7 (120 bp)	0	0	-	-	3	3.93	NS	0.27	NS

^a severe or mild RA compared with controls

^b severe compared with mild RA

NS: not statistically significant

OR: odds ratio

5

The frequency of the polymorphisms in normal subjects ranged from 0% for the 130 bp and 120 bp alleles, to 68% for the 122 bp allele. The genotype frequencies did not deviate from the expected value by Hardy-Weinberg equilibrium. The alleles identified herein appear to correspond closely in length to those initially reported by Ruiz-Linares, which ranged from 122-134 bp (Ruiz-Linares, 1994 Hum. Mol. Genet. 2(9):1508). Such alleles may vary, for example, depending upon the ethnic origin of the subjects and the methodology of characterization (see for example Awata, T. et al. 1994 Diabetologia 37:1159). In some populations, 6-8 alleles encompassing at least 11-15 CA repeats may exist at this site, including the intermediate polymorphism of 128 bp.

15

As shown in this example, patients with severe rheumatoid arthritis differ significantly in the frequency of 2 alleles. The 126 bp allele was present in 73% of patients with severe rheumatoid arthritis compared with 21% of patients with mild rheumatoid arthritis (OR: 10.43, p < 0.0001) and 12% of normal subjects (OR: 19.74, p < 0.0001). In contrast, the 122 bp allele was detected in only 6% of patients with severe rheumatoid arthritis compared with 64% of patients with mild disease (OR: 0.037, p < 0.0001) and 68% of normal subjects (OR: 0.019, p < 0.0001). There was no significant difference in the

20

25

frequencies of the other microsatellite polymorphisms between the three groups of individuals.

Table 2 shows a grouping of the subjects into one of four categories, depending upon their expression of the 126 bp allele and the 122 bp allele. Almost three quarters (73%) of patients with severe rheumatoid arthritis expressed the 126 bp allele without the 122 bp allele, compared with 10% of patients with mild rheumatoid arthritis (OR: 23.56, $p < 0.0001$) and 4% of normal subjects (OR: 60.62, $p < 0.0001$). In contrast, only 6% of patients with severe rheumatoid arthritis expressed the 122 bp allele without the 126 bp allele compared with 54% of patients with mild rheumatoid arthritis (OR: 0.057, $p < 0.0001$) and 70% of normal subjects (OR: 0.029, $p < 0.0001$). The 126 bp and 122 bp alleles were not conjointly expressed by any patients with severe disease compared with conjoint expression in 10% of patients with mild disease (OR: 0.081, $p = \text{NS}$) and conjoint expression in 8% of normal subjects (OR: 0.11, $p = \text{NS}$).

Table 2: Proportion of subjects expressing the 126 bp allele, 122 bp allele, both or neither in the first intron of the IFN γ gene. Controls (n=50), patients with severe RA (n=48) patients with mild RA (n=39).

Categories	Controls	Severe RA			Mild RA				
	%	%	OR ^a	p ^a	%	OR ^a	p ^a	OR ^b	P ^b
126 bp allele	4	73	60.62	<0.0001	10	2.74	NS	23.56	<0.0001
122 bp allele	70	6	0.029	<0.0001	54	0.50	NS	0.057	<0.0001
Both	8	0	0.11	NS	10	1.31	NS	0.081	NS
Neither	18	21	1.20	NS	26	1.57	NS	0.76	NS

^a compared with controls
^b severe compared with mild
 NS: not statistically significant
 OR: odds ratio

Table 3: Results of logistic regression for the effects of HLA-DR, IFN- γ , and clinical measures on the odds of severe disease. Odds ratios and chi-square statistics are marginal (i.e. have been adjusted for all other factors). Odds ratios here reflect the distribution of patients observed rather than underlying prevalence of mild and severe RA. Controls (n=50), patients with severe RA (n=48) patients with mild RA (n=39).

Factor	d.f.	Severe vs. Control χ^2	Severe vs. Mild χ^2	Severe vs. Mild χ^2
HLA-DR	3	11.23*	13.04**	10.66*
IFN- γ	3	65.88**	43.91***	28.09***
RF	2	--	--	9.33**
Age	1	--	--	0.46
Duration	1	--	--	6.57*
Gender	1	--	--	3.84**

Factor	Effect	O.R.	O.R.	O.R.
HLA-DR	H vs. L	23.95*	14.55	48.27
	B vs. L	7.23	0.43	0.63
	N vs. L	2.10	2.15	2.52
IFN- γ	H vs. L	327.09***	107.57***	278.02**
	B vs. L	0.03	0.00	0.00
	N vs. L	19.26***	5.13*	9.95
RF	NA vs. neg			2.10
	pos vs. neg			25.07*
Age	10 years			0.77
Duration	10 years			4.71*
Gender	m vs. f			11.16

*p<0.05; **p<0.01 level; ***p<0.001 level.

HLA-DR: H = QKRR/QRRA, L = DERAA, B = Both, N = Neither

IFN- γ : H = 126 bp allele; L = 122 bp allele; B = Both; N = Neither

These striking results were confirmed in a subsequent and independent group of 12 patients with severe RA who were selected according to the same clinical and laboratory criteria. Seventy-five percent of these patients expressed the 126 bp allele and 8% the 122 bp

allele; when all subjects with severe RA were combined (n=60) the patient frequencies were unchanged from those reported in tables 1 and 2.

Logistic regression was used to examine the influences of IFN- γ polymorphism, HLA
5 DR-B1 genotype (Wayland and Goronzy, 1997, J. Mol. Med. 75:772) and other prognostic
factors. The results are shown in table 3. Inheritance of the INF- γ 126 bp allele is strongly
associated with the presence of severe RA even after accounting for HLA-DRB1
polymorphism, while possession of the IFN γ 122 bp polymorphism is highly negatively
associated with the presence of severe disease. The association of these IFN γ alleles with
10 severe RA is considerably greater than that noted for the most tightly associated MHC class
II alleles or other clinical predictors including gender, age at onset, duration of disease, or
rheumatoid factor positivity.

In accordance with one aspect of the present invention, the diagnostic test for the
15 presence of IFN gamma alleles may be carried out on asymptomatic individuals to assess the
individual's susceptibility to rheumatoid arthritis. In individuals presenting with arthritic
symptoms, the test may be utilized to assess the likelihood of progression to the severe form
of the disease. In accordance with these aspects of the invention, the presence of the 126 bp
allele may be taken as an indication of increased susceptibility to rheumatoid arthritis,
20 including increased susceptibility to progression of the arthritis to the severe form of the
disease, as set out in Table 3.

The diagnostic test may in some embodiments be utilized to determine whether the
IFN gamma alleles are homozygous or heterozygous for example, in the exemplary
25 embodiment, 10% (6/60) of patients with severe rheumatoid arthritis were homozygous for
the 126 bp allele, compared with 3% (1/39) of those with mild disease and 0% (0/50) of
normal controls. In contrast, none of the 60 patients with severe rheumatoid arthritis were
homozygous for the 122 bp allele, compared with 8% (3/39) of those with mild disease and
14% (7/50) of normal controls.

30

EXAMPLE 2

As shown in Figures 1, 2 and 3, 87 patients were segregated into three groups on the basis of their *HLA-DRB1* alleles, on the basis of the charge on the amino acid at position 71, being positive ("+", i.e. lysine (K), arginine (R) or histidine (H)), negative ("-", i.e. glutamate (E) or aspartate (D)) or neutral ("0", the remaining amino acids). Figure 2 shows the *HLA-DRB1* amino acid sequences 70-74 for both alleles for patients with severe RA. Figure 3 shows the *HLA-DRB1* amino acid sequences 70-74 for both alleles for patients with mild RA. Individuals are segregated in the chart of Figure 1 into three groups based on their *HLA-DRB1* sequence:

- i) A+/+ individuals are homozygous for a positive amino acid at position 71;
- ii) A+/0 individuals are heterozygous, having a positive amino acid allele and a neutral amino acid allele;
- iii) A-/* individuals have at least one copy of an allele with a negative amino acid at position 71.

With respect to the IFN-gamma alleles in the chart of Figure 1 "+" indicates a high risk allele, while "-" indicates a low risk allele. For example, individuals who are homozygous for the high risk allele are grouped on the branch of the tree denoted by "+/+".

The risk analysis chart indicates, for example, that patients homozygous a positive amino acid at position 71 of *HLA-DRB1* and homozygous for the high risk IFN allele suffer from severe RA in 24 out of 26 cases, while patients having at least one *HLA-DRB1* allele with a negative amino acid (shown as "-/*") who are also homozygous for the low risk IFN allele ("-/-) present with mild RA in 7 out of 7 cases.

Although various embodiments of the invention are disclosed herein, many adaptations and modifications may be made within the scope of the invention in accordance with the common general knowledge of those skilled in this art. Such modifications include the substitution of known equivalents for any aspect of the invention in order to achieve the same result in substantially the same way. Numeric ranges are inclusive of the numbers defining the range. In the claims, the word "comprising" is used as an open-ended term, substantially equivalent to the phrase "including, but not limited to".

WHAT IS CLAIMED IS:

1. A method of diagnosis, comprising:
 - a) identifying a patient at risk of an arthritis, the patient having an interferon gamma gene;
 - b) testing the patient to characterize a polymorphism in the interferon gamma gene.
2. The method of claim 1, wherein the polymorphism occurs within a variable length dinucleotide repeat region within a first intron.
3. The method of claim 2, wherein the variable length dinucleotide repeat region is at least partly located between nucleotides 1349 and 1373 in the interferon gamma gene.
4. The method of claim 1, 2 or 3 wherein the characterization of the polymorphism is carried out so as to be capable of identifying alleles selected from the group consisting of a 126bp allele and a 122bp allele.
5. The method of any one of claims 1 through 4 wherein the characterization of the polymorphism is carried out so as to be capable of resolving alleles having a different number of CA repeats in a portion of the first intron of the interferon gamma gene.
6. The method of any one of claims 1 through 5, wherein the arthritis is rheumatoid arthritis.
7. The method of any one of claims 1 through 6 wherein the patient is caucasian.
8. The method of any one of claims 1 through 7 wherein the step of identifying the patient at risk of the arthritis comprises diagnosing the patient with rheumatoid arthritis.
9. The method of any one of claims 1 through 8, wherein the step of identifying the patient at risk of the arthritis comprises diagnosing the patient with a symptom selected from the group consisting of joint erosions, elevated erythrocyte sedimentation rate, C-reactive protein, polyarticular disease, joint deformities, radiological evidence of subchondral erosions, extra-articular arthritis, and the presence of rheumatoid factor.
10. The method of any one of claims 1 through 9, wherein the characterization of the polymorphism comprises amplification of a variable length dinucleotide repeat region.

11. The use an allele of an interferon gamma gene to diagnose a patient at risk of an arthritis.
12. The use of the allele according to claim 11, wherein the allele is selected from the group consisting of alleles comprising a variable length dinucleotide repeat region within a first intron of the interferon gamma gene.
13. The use of the allele according to claim 12, wherein the variable length dinucleotide repeat region comprises a variable number of CA repeats.
14. The use of the allele according to claim 11, 12 or 13, wherein the allele is selected from the group consisting of a 126bp allele and a 122bp allele.
15. A method of diagnosing the susceptibility of a patient to arthritis, the patient having an interferon gamma gene, comprising testing the patient to characterize a polymorphism in a first intron of the interferon gamma gene.
16. A method of treating a patient having an interferon gamma gene, comprising testing the patient to characterize a polymorphism in the interferon gamma gene; and, treating the patient for arthritis if the polymorphism is indicative that the patient is at risk of an arthritis.
17. The method of claim 16 wherein the polymorphism occurs within a variable length dinucleotide repeat region within a first intron.
18. The method of any one of claims 1 through 17 further comprising testing the patient to characterize a polymorphism in an HLA gene.
19. The method of claim 18 wherein the HLA gene comprises an *HLA-DRB1* locus.
20. The method of claim 18 further comprising testing the patient to characterize a portion of the sequence of an HLA protein.
21. The method of claim 20 wherein the HLA protein is a Class II protein.
22. The method of claim 20 wherein the HLA protein is a HLA-DRB1 protein.
23. The method of claim 22 wherein the portion of the sequence is amino acid 71.

Figure 1




Figure 2

Code No.	Allele 1					Allele 2				
	70	71	72	73	74	70	71	72	73	74
01S	Q	K	R	A	A	Q	R	R	A	A
02S	Q	K	R	G	R	Q	K	R	A	A
03S	Q	K	R	A	A	D	R	R	G	Q
04S	Q	K	R	A	A	Q	K	R	A	A
06S	Q	K	R	A	A	D	R	R	G	Q
07S	Q	K	R	G	R	D	E	R	A	A
08S	Q	R	R	A	A	D	R	R	G	Q
09S	D	E	R	A	A	Q	R	R	A	A
11S	D	R	R	A	A	Q	K	R	A	A
12S	Q	A	R	A	A	Q	R	R	A	A
13S	Q	K	R	A	A	D	R	R	G	Q
15S	Q	K	R	A	A	Q	R	R	A	E
16S	Q	R	R	A	A	Q	A	R	A	A
17S	Q	R	R	A	A	Q	R	R	A	A
18S	Q	R	R	A	A	D	R	R	A	A
19S	Q	K	R	A	A	Q	R	R	A	A
20S	Q	R	R	A	A	D	R	R	A	L
21S	Q	K	R	A	A	R	R	R	A	A
22S	Q	R	R	A	A	Q	K	R	A	A
23S	Q	K	R	A	A	D	R	R	A	A
24S	Q	R	R	A	A	D	R	R	G	Q
25S	Q	R	R	A	A	Q	R	R	A	A
26S	Q	A	R	A	A	Q	R	R	A	A
27S	Q	K	R	A	A	Q	K	R	A	A
28S	Q	K	R	A	A	D	R	R	G	Q
29S	Q	K	R	A	A	Q	K	R	A	A
30S	Q	R	R	A	A	Q	A	R	A	A
31S	Q	R	R	A	A	Q	A	R	A	A
32S	Q	A	R	A	A	Q	K	R	G	R
33S	Q	K	R	G	R	Q	R	R	A	A
34S	Q	K	R	A	A	R	R	R	A	E
36S	Q	K	R	A	A	D	R	R	G	Q
37S	Q	R	R	A	A	D	R	R	G	Q
39S	Q	K	R	G	R	Q	R	R	A	A
40S	D	R	R	A	A	D	R	R	G	Q
41S	Q	A	R	A	A	Q	K	R	A	A
42S	D	R	R	A	A	Q	R	R	A	A
43S	Q	K	R	G	R	Q	R	R	A	A
44S	Q	A	R	A	A	Q	K	R	A	A
46S	Q	K	R	A	A	Q	R	R	A	A
49S	Q	K	R	G	R	D	R	R	A	A
50S	Q	R	R	A	A	Q	K	R	A	A
51S	D	E	R	A	A	Q	K	R	A	A
54S	Q	K	R	G	R	Q	K	R	A	A
55S	Q	K	R	A	A	Q	K	R	G	R
56S	Q	K	R	A	A	Q	K	R	A	A
57S	Q	A	R	A	A	D	R	R	A	A
58S	Q	K	R	G	R	D	R	R	G	Q

Figure 3

Code No.	Allele 1					Allele 2				
	70	71	72	73	74	70	71	72	73	74
01M	D	K	R	A	A	Q	R	R	A	A
02M	D	R	R	A	L	Q	K	R	A	A
03M	Q	R	R	A	A	D	R	R	G	Q
04M	Q	K	R	G	R	D	R	R	G	Q
05M	Q	K	R	G	R	D	E	R	A	A
07M	Q	A	R	A	A	R	R	R	A	E
08M	Q	A	R	A	A	Q	A	R	A	A
09M	D	E	R	A	A	R	R	R	A	A
10M	Q	R	R	A	A	Q	R	R	A	A
11M	Q	K	R	G	R	Q	K	R	A	A
12M	D	R	R	A	A	D	R	R	G	Q
13M	Q	A	R	A	A	D	E	R	A	A
14M	Q	K	R	A	A	D	R	R	G	Q
15M	D	E	R	A	A	Q	K	R	A	A
17M	Q	A	R	A	A	Q	K	R	A	A
18M	Q	A	R	A	A	Q	K	R	G	R
19M	Q	R	R	A	A	Q	R	R	A	A
20M	Q	R	R	A	A	D	E	R	A	A
21M	D	E	R	A	A	D	R	R	G	Q
23M	Q	K	R	G	R	D	E	R	A	A
24M	Q	R	R	A	A	D	E	R	A	A
25M	Q	A	R	A	A	D	R	R	A	A
26M	Q	K	R	A	A	Q	K	R	A	A
27M	D	R	R	A	L	D	E	R	A	A
28M	Q	K	R	A	A	R	R	R	A	A
30M	Q	K	R	A	A	Q	R	R	A	A
31M	D	R	R	A	L	D	R	R	A	L
33M	Q	R	R	A	A	D	R	R	G	Q
34M	Q	K	R	G	R	D	E	R	A	A
36M	Q	A	R	A	A	D	E	R	A	A
38M	D	E	R	A	A	D	R	R	G	Q
39M	R	R	R	A	E	Q	R	R	A	A
40M	Q	R	R	A	A	Q	A	R	A	A
41M	Q	R	R	A	A	R	R	R	A	E
44M	D	R	R	A	A	Q	K	R	G	R
45M	Q	R	R	A	A	Q	A	R	A	A
46M	Q	K	R	G	R	D	R	R	A	A
47M	Q	K	R	A	A	D	R	R	G	Q
50M	D	R	R	A	A	Q	A	R	A	A

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
15 March 2001 (15.03.2001)

PCT

(10) International Publication Number
WO 01/18240 A3

(51) International Patent Classification⁷: **C12Q 1/68**

University-Industry Liaison Office, IRC Building, Room
331, 2194 Health Sciences Mall, Vancouver, British
Columbia V6T 1Z3 (CA).

(21) International Application Number: **PCT/CA00/01043**

(22) International Filing Date:
8 September 2000 (08.09.2000)

(72) Inventors; and

(75) Inventors/Applicants (for US only): **KEOWN, Paul**
[CA/CA]; Immunology Laboratory, Vancouver General
Hospital, 855 West 12th Avenue, Vancouver, British
Columbia V5Z 1M9 (CA). **KHANI-HANJANI, Abbas**
[CA/CA]; Immunology Laboratory, Vancouver General
Hospital, 855 West 12th Avenue, Vancouver, British
Columbia V5Z 1M9 (CA). **HOAR, David** [CA/CA];
Immunology Laboratory, Vancouver General Hospital,
855 West 12th Avenue, Vancouver, British Columbia V5Z
1M9 (CA).

(25) Filing Language: English

(26) Publication Language: English


(30) Priority Data:
2,282,062 8 September 1999 (08.09.1999) CA
60/160,618 20 October 1999 (20.10.1999) US
2,303,504 10 April 2000 (10.04.2000) CA

(71) Applicant (for all designated States except US): **THE
UNIVERSITY OF BRITISH COLUMBIA** [CA/CA];


(74) Agents: **KINGWELL, Brian, G.** et al.; Smart & Biggar,
Box 11560, Vancouver Centre, 650 West Georgia Street,
Suite 2200, Vancouver, British Columbia V6B 4N8 (CA).

[Continued on next page]

(54) Title: **DIAGNOSTIC AND THERAPEUTIC METHODS IN AUTOIMMUNE DISEASE**



(57) Abstract: In one aspect, the invention provides a method of diagnosis. The diagnostic method may include steps of identifying a patient at risk of an arthritis, the patient having an interferon gamma gene. The patient may be tested to characterize a polymorphism in a first intron of the interferon gamma gene. The polymorphism may comprise a variable length dinucleotide repeat region within the first intron, and the dinucleotide repeat region may be located at least partly between nucleotides 1349 and 1373 in the interferon, gamma gene. The method may be carried out so as to be capable of identifying alleles such as the 126 bp allele and the 122 bp allele, as further described herein. The polymorphisms may be distinguished based on a difference in the number of CA repeats in a portion of the first intron of the interferon gamma gene. The invention may also comprise testing a patient for a polymorphism is an HLA protein (or gene), such as the HLA-DRB1 protein.



WO 01/18240 A3



(81) **Designated States (national):** AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) **Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,

IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) **Date of publication of the international search report:**

8 November 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.